Teva Comments on Pfizer Press Release Regarding Azithromycin

Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) commented on Pfizer’s February 8th press release regarding azithromycin. Although Teva has not yet seen the Citizen Petition or the complaint relating to the infringement actions referenced in the press release, Teva believes that these allegations are baseless and without merit.

Source: Teva Pharmaceutical Industries Ltd.